05 December 2023
05 December 2023
As the year comes to a close the Clinical Trials Arena team look back at the stand-out trials of 2023.
A statement issued by leading industry bodies emphasises climate change as an urgent health challenge at COP28, as the president defends fossil fuel use.
The inavolisib combination regimen offered 'meaningful' improvement against the placebo arm in the first-line setting.
ALTO-300-treated patients with an EEG biomarker achieved better clinical response in the major depressive disorder Phase II trial.
Palvella will receive $5m as an upfront payment, with Ligand getting 8%-9.8% in tiered royalties on worldwide sales of Qtorin rapamycin.
Viriom will initiate two Australia-based Phase I trials investigating its assets in influenza and Covid-19 in 2024, which may lead to studies in the US.
The trial met its primary endpoint, with EYP-1901 offering a statistical non-inferiority BCVA variation against control.
The hormone-free contraceptive trial is set to enrol around 250 patients as the company gears up to seek FDA approval.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
